Business
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
– Podium presentation on March 22, 2023 – – Company to host an Industry Forum to discuss its new approach to protecting dystrophic muscle featuring a key
About this update from Edgewise Therapeutics, Inc.
[{"type":"text","content":"\n– Podium presentation on March 22, 2023 –\n\n– Company to host an Industry Forum to discuss its new approach to protecting dystrophic muscle featuring a key opinion leader –\n\n BOULDER, Colo.--(BUSINESS WIRE)--\nEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that the company will present on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference. The conference will take place at the Hilton Anatole in Dallas, TX from March 19-22, 2023.\n\nDetails of the Edgewise presentations at MDA:\n\nPodium Presentation in Clinical Trial Updates Session\nTitle: Effects of EDG-5506, a Fast Myosin Modulator, on Biomarkers of Muscle Damage and Function in Adults with Becker Muscular Dystrophy (BMD) (Poster #73)\nPresenter: Han C. Phan, M.D., Head of Research & Principal Investigator, Pediatric Neurologist, Rare Disease Research, LLC\nDate: Wednesday, March 22, 2023, 2:30 – 2:45 pm CT\n\nScientific Posters\nTitle: Plasma Metabolic Profiling Suggests Enrichment of Glycolytic Pathways Over Fatty Acid Oxidation in Becker Muscular Dystrophy (Poster #71)\nTitle: Fast Skeletal Myosin Modulator EDG-5506 Confers Additional Protection to MDX Mice Receiving Glucocorticoid (Poster #72)\nTitle: Characterization of Short- and Long-Term Proteomic Response to the Fast Skeletal Myosin Inhibitor, EDG-5506, in Becker Muscular Dystrophy (Poster #119)\n\nA companion poster presentation will be available for Dr. Phan’s presentation (poster 73). Posters will be viewable both in-person during the conference from March 19-21, 2023 and showcased in the Exhibit Halls from 6:00-8:00 pm CT. The full MDA 2022 Conference program is available here: https://mdaconference.org.\n\nThe Edgewise presentation and posters will be available on the Edgewise website when they are presented.\n\nEdgewise Industry Forum with Key Opinion Leader\n\nOn March 21, 2023, at 12 pm CT, Edgewise is sponsoring an Industry Forum, “Targeting Fast Muscle Myosin: A Novel Approach to Protecting Muscle in the Dystrophinopathies.” The forum will feature leading neuro...